 2020 Q3 Earnings Call Summary

Chemed Corporation reported its Q3 2020 operating results, which showed sequential improvement from the second quarter. VITAS Healthcare Corporation's hospice segment operations continued to be impacted by the pandemic, but the federal government's support allowed the company to generate admissions growth. Roto-Rooter services demand showed significant improvement from the second quarter, driven by the relaxation of regulations and the reopening of the economy. Chemed is currently estimating $8.6 million for Medicare Cap billing limitations for calendar year 2020. The company's full year 2020 adjusted EBITDA margin prior to Medicare Cap is estimated to be 21%. Chemed's full year 2020 revenue growth is forecasted to be 12.5% to 13%, assuming 2.7% of seasonal sequential revenue growth from the third quarter to the fourth quarter of 2020. The company's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15.